Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep70 | Adrenal cortex | ECE2015

Prevalence of hypercortisolism in type 2 diabetes patients: a meta-analysis

Steffensen Charlotte , Pereira Alberto , Dekkers Olaf M , Jorgensen Jens Otto

Background: Type 2 diabetes (T2D) and hypercortisolism associated with Cushing’s syndrome (CS) share clinical characteristics such as hypertension, dyslipidaemia, hyperglycaemia, and obesity. Several studies have recorded a relatively high prevalence of hypercortisolism in T2D, which may have therapeutic implications. The aim of this systematic review and meta-analysis was to assess the prevalence of hypercortisolism in T2D patients.Methods: Origina...

ea0049gp190 | Pituitary & endocrine Tumours | ECE2017

Safety of long-term growth hormone (GH) treatment in adults with GH deficiency (GHD): an analysis from the NordiNet® International Outcome Study

Jorgensen Jens Otto , Popovic-Brkic Vera , Pournara Effie , Pedersen Birgitte , Chudecka Anita , Strasburger Christian

Background: Long-term safety data (1998 to mid-2016) are reported for adult patients with GHD treated with GH (Norditropin® (somatropin), Novo Nordisk) as prescribed by treating physicians in the real-life clinical setting and enrolled in NordiNet® International Outcome Study (IOS) (NCT00960128), a non-interventional, multicentre study.Objective and hypotheses: To describe and report safety data and incidence rates (IRs) (...

ea0049ep63 | Adrenal cortex (to include Cushing's) | ECE2017

Treatment with modified-release hydrocortisone for 6 months: A clinical audit in 15 patients with adrenal insufficiency

Steffensen Charlotte , Andersen Marianne , Feldt-Rasmussen Ulla , Kistorp Caroline , Jorgensen Jens Otto L

Background: Patients with adrenal insufficiency (AI) exhibit increased morbidity, mortality and impaired quality of life (QoL) and conventional hydrocortisone replacement does not mimic the endogenous circadian pattern and may compromise adherence. A modified – release hydrocortisone formulation (Plenadren) for once-daily use is licensed in order to meet these needs.Objective: To audit the effects of treatment change from HC to Plenadren in an out-p...

ea0041ep595 | Endocrine tumours and neoplasia | ECE2016

Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients

Arlien-Soborg Mai C. , Alvarson Elin , Dal Jakob , Jorgensen Jens Otto L.

Context: The nadir serum GH level during glucose suppression (OGTT) is recommended in patients treated by surgery, but not during SA treatment. We have shown that patients considered controlled by SA don’t suppress serum GH during OGTT and have impaired disease-specific QoL as compared to patients controlled by surgery. We hypothesize SA treated patients also don’t suppress GH in response to mixed meals.Aim: To compare GH levels during two mixe...

ea0041ep704 | Growth hormone IGF axis - basic | ECE2016

Concomitant medication in growth hormone (GH)-treated patients with adult GH deficiency (AGHD): an analysis from NordiNet® International Outcome Study (IOS)

Hoybye Charlotte , Pournara Effie , Pedersen Birgitte Tonnes , Jorgensen Jens Otto Lunde

Introduction: Patients with AGHD receiving GH often have comorbidities requiring concomitant treatment. We evaluated patterns of concomitant medication use relative to GH therapy initiation in patients with AGHD.Methods: Patients with AGHD with data on concomitant medications enrolled in NordiNet® IOS (NCT00960128), an international, non-interventional study, receiving GH (Norditropin®, Novo Nordisk A/S, Denmark) therapy w...

ea0035p673 | Growth hormone IGF axis basic | ECE2014

Incidence and late prognosis of acromegaly in Denmark: preliminary data

Dal Jakob , Feldt-Rasmussen Ulla , Andersen Marianne , Kristensen Lars , Laurberg Peter , Sorensen Henrik , Jorgensen Jens Otto

Introduction: Acromegaly is a rare disease caused by GH hypersecretion from a pituitary adenoma. However, accurate estimates of incidence and prevalence are scarce and not based on nationwide populations. It is well known that surgical cure may normalize mortality and improve morbidity but similar data are not available for patients receiving medical treatment.Method: We first validated the ICD-8 and ICD-10 diagnosis codes for acromegaly in The National ...

ea0070aep676 | Pituitary and Neuroendocrinology | ECE2020

European Society of Endocrinology audit and multi-country comparison of Adult Growth Hormone Deficiency (AGHD) treatment in clinical practice in Europe and Australia; –how closely are protocols and best practice recommendations followed

Martel-Duguech Luciana , Screen Nik , Jorgensen Jens Otto L , Korbonits Marta , Johannsson Gudmundur , Webb Susan M

Background: Current guidelines recommend that susceptible patients should be tested and treated for AGHD. Still, it is not universally recognised as a distinct entity and reimbursement of GH replacement therapy is not available in some countries.Aim: 1) to record current practice of AGHD management throughout Europe and benchmark it against existing guidelines, 2) to evaluate educational status of health care professionals.Patients...

ea0032oc1.6 | Pituitary & Molecular Endocrinology | ECE2013

Management of euvolemic hyponatremia attributed to SIADH in the hospital: interim results from a prospective, observational, multi-center, global registry

Peri Alessandro , Verbalis Joseph , Greenberg Arthur , Johannsson Gudmundur , Ball Steven , Jorgensen Jens Otto , Chiodo Joseph

Introduction: Hyponatremia (HN) is the most common electrolyte disorder of hospitalized patients (pts). It occurs in up to 28% of in-pts, increases the in hospital risk of death by 1.47 fold, and is associated with significantly higher mortality risk following discharge. The HN Registry is the first large scale, international effort to document the clinical characteristics, treatments used, and impact of HN in hospital settings.Methods: After informed co...

ea0032p875 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Thirty-day mortality in acute non-surgical patients admitted with hyponatremia

Holland-Bill Louise , Christiansen Christian , Ring Troels , Toft Sorensen Henrik , Lunde Jorgensen Jens Otto

Introduction: Hyponatremia (serum sodium ≤135 mmol/l), the most common electrolyte disorder encountered, has been associated with increased mortality in patients with particularly cancer, heart failure, chronic kidney and liver disease. However, evidence of the clinical implications in broader populations is scarce, and uncertain due to confounding from preexisting disease. We aimed to examine the association between admission-hyponatremia and 30-day mortality in acute n...

ea0022p508 | Growth factors | ECE2010

Insulin resistance induced by GH is transient and reversible: glucose clamp studies during different ambient GH levels in GH-deficient adults

Krusenstjerna-Hafstrom Thomas , Moller Niels , Christiansen Jens Sandahl , Jessen Niels , Jorgensen Jens Otto Lunde

Background: The impact of GH on insulin sensitivity is ambiguous since both long standing GH-deficiency as well as acute GH exposure and prolonged GH-excess are associated with insulin resistance.Aim: To test the hypotheses that the insulin antagonistic effect of GH i) is dynamic and depend on ambient GH levels and ii) subsides gradually with time after GH exposure.Methods: Eight GHDA participated in a randomised crossover study. E...